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RWRWRW-NH2 (MP196) is an amphipathic hexapeptide that targets the bacterial
cytoplasmic membrane and inhibits cellular respiration and cell wall synthesis. In previous
studies it showed promising activity against Gram-positive bacteria and no significant
cytotoxicity or hemolysis. MP196 is therefore used as lead structure for developing
more potent antibiotic derivatives. Here we present a more comprehensive study on
the parent peptide MP196 with regard to clinically relevant parameters. We found that
MP196 acts rapidly bactericidal killing 97% of initial CFU within 10 min at two times
MIC. We were unable to detect resistance in standard 24 and 48 h resistance frequency
assays. However, MP196 was effective against some but not all MRSA and VISA strains.
Serum binding of MP196 was intermediate and we confirmed its low toxicity against
mammalian cell lines. MP196 did neither induce NFκB activation nor cause an increase
in IL8 levels at 250µg/mL, and no IgE-dependent activation of basophil granulocytes was
detected at 500 µg/mL. Yet, MP196 demonstrated acute toxicity in mice upon injection
into the blood stream. Phase contrast microscopy of mouse blood treated with MP196
revealed a shrinking of erythrocytes at 250 µg/mL and severe morphological changes
and lysis of erythrocytes at 500 µg/mL. These data suggest that MP196 derivatization
directed at further lowering hemolysis could be instrumental in overcoming acute toxicity.
The assessment of hemolysis is a critical step in the evaluation of the clinical potential
of promising antimicrobial peptides and should be accompanied by microscopy-based
morphological analysis of blood cells.
Keywords: antimicrobial peptide, toxicity tests, acute, antimicrobial cationic peptides, antimicrobial peptide
resistance, toxicity mechanisms
INTRODUCTION
Resistance of microorganisms against antibiotics has developed into a major health problem.
According to a 2015 report, antimicrobial resistance accounts for 700,000 deaths worldwide
each year and numbers are rising (O’Neill, 2015). Multi-resistant bacteria, so-called superbugs,
constitute a particular problem. In the US alone, multi-resistant Staphylococcus aureus (MRSA)
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cause over 100,000 life-threatening infections per year (Klevens
et al., 2007) and in some European countries MRSA prevalence
in blood cultures exceeds 50% (ECDC/EMEA Joint Working
Group, 2009). Resistances against last line of defense antibiotics
are on the rise (Stefani et al., 2015), while at the same
time, antibiotic approval rates declined drastically (Spellberg
et al., 2015). Therefore, novel antibiotic compounds and
alternative antimicrobial strategies are urgently needed. Several
drugs and therapeutic antibodies are currently in early clinical
development (Vuong et al., 2016). Additional approaches to
keeping up with the rapid development and spread of bacterial
resistance include optimizing hospital hygiene (Köck et al.,
2014), systematic MRSA decolonization (Köck et al., 2014),
MRSA-selective phage therapy (Matsuzaki et al., 2003), or
maggot therapy to clean wounds from necrotic tissue (Bowling
et al., 2007). Several natural products with known antibacterial
properties are evaluated for topical use as wound dressings
against MRSA, e.g., oak extract or honey (Blaser et al., 2007;
Kwakman et al., 2010; Sherlock et al., 2010; Graham, 2014).
Seeking alternative or adjunct therapy options, antimicrobial
peptides are currently re-evaluated. This compound class
occurs naturally in all domains of life and is part of
the innate immune system (Brogden and Brogden, 2011).
Over 2500 peptides are currently listed in the Antimicrobial
Peptide Database (http://aps.unmc.edu/AP/main.php), not even
covering a fraction of the variety of synthetic peptides that
have been produced over the last years. In addition to
being antibacterial, many of these peptides possess antiviral,
antifungal, anti-parasite, or anticancer activity and/or can act
as immune enhancers or modulators (Mansour et al., 2014).
Importantly, many peptides are hardly affected by bacterial
resistance (Yeaman and Yount, 2003). Thus, antimicrobial
peptides constitute an enormous resource of potential drug
candidates.
While naturally occurring peptides are sometimes difficult
to isolate or synthesize, smaller chemically designed peptides
are an attractive alternative (Haug et al., 2004). Many natural
peptides share a structural motif characterized by arginine (R)
and tryptophane (W) residues. In an attempt to find the minimal
pharmacophore of such RW-rich peptides, the hexapeptide
RWRWRW-NH2 (MP196) was found to be the shortest RW-
based sequence that still possesses good antibacterial activity
(Strøm et al., 2003). Since many cationic antimicrobial peptides
are cytotoxic and/or hemolytic, clinical application of these
highly effective antimicrobials is limited (Jamasbi et al., 2014).
MP196 was not significantly hemolytic or cytotoxic, and
MP196—lipid interactions were shown to be highly selective
for bacterial over mammalian membrane mimics (Albada et al.,
2012a; Wenzel et al., 2014). Therefore, it was chosen as
a peptide lead structure and subjected to several chemical
modification approaches including organometallic (Albada et al.,
2012a) and fatty acyl derivatization (Albada et al., 2012b) and
multivalency studies (Hoffknecht et al., 2015, 2016). Several of
the resulting compounds displayed drastically improved activity
against both Gram-positive and Gram-negative pathogens but
also enhanced hemolytic potential (Albada et al., 2012a,b).
Systematic exchange of L- to D-amino acid residues resulted
in optimized non-hemolytic linear peptides with excellent anti-
MRSA activity (Albada et al., 2013, 2014). Importantly, neither
organometallic nor fatty acyl modifications significantly changed
the antibacterial mechanism of action compared to the parent
peptide MP196, which integrates into the cytoplasmic membrane
and by deforming the lipid bilayer delocalizes essential proteins
involved in respiration and cell wall biosynthesis as well as cell
division (Wenzel et al., 2014, 2016). Since it targets such an
essential structure as the bacterial membrane and affects different
membrane-associated processes at the same time, fast resistance
development was not expected, making MP196-derived peptides
interesting candidates for further antibiotic development.
In order to evaluate the potential of these short RW-rich
peptides for antibacterial treatment and to chart new avenues
for further structural optimization, we investigated resistance
development and the toxicity profile of the original MP196
peptide as a representative of the whole group.
METHODS
Antibiotics
MP196, FcPNA, and aurein 2.2 were synthesized as described
previously (Chantson et al., 2006; Pan et al., 2007; Patra
et al., 2010). Trimethoprim, rifampicin, and erythromycin were
purchased from Sigma-Aldrich. MP196, FcPNA, rifampicin, and
trimethoprim were dissolved in sterile DMSO, aurein 2.2 in
sterile water, and erythromycin in ethanol. Unless otherwise
noted, experiments were performed in biological duplicates.
Minimal Inhibitory Concentration (MIC)
MICs were tested against S. aureus DSM 20231 (type strain),
ATCC 43300 (MRSA), COL (MRSA), SG511 (VISA), and Mu50
(VISA) in Mueller Hinton (MH) broth in a microtiter plate
assay according to Clinical and Laboratory Standards Institute
(CLSI) guidelines. In short, serial peptide dilutions were prepared
in MH, inoculated with 5 × 105 colony-forming units (CFU)
per mL, and incubated for 16 h at 37◦C. Inoculated medium
without peptide served as positive control, uninoculated medium
as negative control. The lowest concentration that prevented
visible growth was reported as MIC.
Binding to Bovine Serum Protein
Antibiotics were dissolved in 0.9% NaCl or undiluted bovine
serum, respectively. MICs against B. subtilis 168 were determined
on MH agar plates in a hole diffusion assay as described below.
Plasma binding was determined by comparing MICs of the
peptide incubated with and without bovine serum.
Survival Rates
MICs against Bacillus subtilis 168 were determined in a standard
test tube assay as described previously (Wenzel et al., 2011).
Survival rates were determined in Luria Bertani (LB) broth
supplemented with 18 µg/mL MP196, 4 µg/mL FcPNA, 20
µg/mL aurein 2.2, or 0.18 µg/mL trimethoprim, respectively.
Antibiotic solutions were inoculated with 5 × 105 CFU/mL and
aerobically incubated for 10 min at 37◦C. Aliquots were plated
on LB agar plates without antibiotic and incubated at 37◦C for
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 August 2016 | Volume 4 | Article 86
Wenzel et al. MP196 Resistance and Toxicity Profiles
16 h. Experiments were performed in technical duplicates and
biological triplicates.
Resistance Frequency
MICs against B. subtilis 168 (trpC2) (Anagnostopoulos and
Spizizen, 1960) were determined on agar plates in a hole diffusion
assay. 108 CFU were plated on MH agar plates and 100 µL
of antibiotic dilutions (in 0.9% NaCl) were added to 6 mm
holes. NaCl solution alone served as negative control. Plates were
incubated at 37◦C for 16 h. Notably, the MIC on MH agar
plates (45 µg/mL) was much higher as compared to liquid MH
(2 µg/mL). For determining resistance frequency, 108 cells of
B. subtilis 168 were plated on MH agar plates with four-fold
MIC (180 µg/mL MP196, 3.2 µg/mL rifampicin, 2.4 µg/mL
erythromycin) or plates without antibiotic. Plates were incubated
at 37◦C and evaluated after 24 and 48 h.
Toxicity against Mammalian Cell Lines
NRK-52E rat kidney epithelial cells were cultured in DMEMPAN
(PAN Biotech, Cat.-Nr. P04-03500) and CCRF-CEM human
T-cell lymphoblast cells in RPMI 1640 medium. Both media were
supplemented with 10% calf serum (FCS), 100 U/mL penicillin,
100 µg/mL streptomycin, and 1% L-glutamine at 37◦C in a 5%
CO2 atmosphere. 2.5 × 10
3 NRK-52E cells or 6.2 × 104 CCRF-
CEM cells were incubated with 200, 66, 22.2, 7.4, 2.4, 0.82,
0.27, and 0.09 µg/mL MP196 at 37◦C for 72 h in a 5% CO2
atmosphere. Ten microliters of Alamar Blue (Invitrogen) were
added to the plates and fluorescence was detected after 3 h with
a Tecan Spectra Fluor Plus instrument (excitation at 550 nm,
emission at 595 nm) as readout for cell viability. Each MP196
concentration was tested in technical and biological duplicates.
Murine Model of Acute Toxicity
Acute toxicity in mice was performed in accordance with
the institutional proposal (M56/2012-A-02) approved by
the Landesamt für Natur, Umwelt und Verbraucherschutz
Nordrhein-Westfalen. Animal care and use was performed
under federal guidelines. Mice were fed and received sterile
water ad libitum. Animals were euthanized according to the
institutional approval and federal guidelines. MP196 was
solubilized in sterile 0.9% NaCl for intravenous injection into
mice. A 5 mL/kg body weight volume was used to administer 5,
10, and 25 mg/kg body weight of the test compound or vehicle
alone (0.9% NaCl) into the tail vein. In accordance with the
animal welfare guidelines the N for these early toxicity tests was 1
animal per group. Mice were monitored for behavior and health
conditions constantly for the first 2 h after each single injection.
Monitoring was continued hourly between 3 and 8 h, at 16 h, and
daily for 5 days after initial injection.
NF-κB Activation
RT4 bladder epithelial cells (ATCC HTB-2) were stably
transfected with a plasmid construct containing an NF-κB
promoter with a luciferase reporter. Cells were cultured in
RPMI 1640 medium containing 10% FCS, 2.5% HEPES, 1%
L-glutamine, and the eukaryotic antibiotic G418 (0.5 mg/mL,
Sigma Aldrich) at 37◦C in 5% CO2. Cells were passaged and
seeded into 96-well white plastic clear-bottomed plates (Corning)
at 5 × 104 cells per well and allowed to grow for 48–72 h
until confluent. Cells were then challenged with either flagellin
(isolated from E. coli) at concentrations from 10 ng to 200 ng/mL
as a positive control or the peptide MP196 at concentrations
from 10 ng to 25 ug/mL, 250 and 500 µg/mL. Negative controls
containing media only, 0.05% DMSO, or 0.25% DMSO were
included. After challenge for 1, 6, and 24 h, cells were lysed using
RLB (Promega) and stored overnight at−80◦C before addition of
luciferin (Promega). The resulting luminescence was read using
an Omega Fluostar plate reader (BMG Labtech).
IL8 Induction
IL8 levels in RT4 bladder cells were measured with an ELISA
assay. To this end, ATCC HTB-2 cells were cultured as described
above and seeded into 12-well plastic plates at 2 × 105 cells per
well. Cells were grown for 72 h until confluent and challenged
for 6 and 24 h with either 50 ng/mL flagellin (isolated from E.
coli) as a positive control, with 0.25% DMSO as negative control,
or with 250 µg/mL MP196. Media was collected post-challenge
and IL-8 production was measured by ELISA (R&D Systems) as
per manufacturer’s instructions with concentrations as follows:
capture antibody 4 µg/mL, detection antibody 20 ng/mL, media
diluted 1 in 50 in 1x PBS with 0.1% BSA. A negative control
and standard curve were included on each plate. Plates were read
using an Omega Fluostar Plate reader (BMG Labtech) at 450 and
540 nm and concentrations calculated using blank-corrected data
fitted to the standard curve using 4-parameter fit, after which the
dilution factor was applied.
Flow Cytometric Detection of Basophil
Activation
Basophil activation was tested using the Basotest reagent kit
(Glycotope Biotechnology) according to the manufacturer’s
instructions. This test involves a phycoerythrin (PE)-conjugated
anti-IgE and a fluorescein isothiocyanate (FITC)-conjugated
anti-CD63 monoclonal antibody. Heparinized whole blood
from one donor was incubated with 1, 5, 10, 25, 100, or
500 µg/mL MP196 solution, 5% DMSO, or 2 µM N-formyl-
Met-Leu-Phe (positive control). Anti-IgE-PE/anti-gp53-FITC
(CD63)-stained cells were excited at 488 nm and fluorescence
was measured with a FACSCanto II-cytometer equipped with
FACSDiva software (Becton-Dickinson). About 1000 basophilic
granulocytes expressing high amounts of IgE per sample were
acquired by fluorescence triggering in the FL2 channel (PE). An
analysis gate was set in the SSC/FL2 dot plot around basophilic
cells. Markers were set for FL2 and FL1 was analyzed using the
same marker positions. The percentage of cells expressing the
antigen gp53 was analyzed in FL1 (FITC).
Phase Contrast Microscopy of Mouse
Blood
Blood was collected from surplus animals after sacrificing. The
procedure has been approved by the Body of Internal Animal
Welfare FNWI, University of Amsterdam. After sacrificing,
whole blood was drained from mice into anticoagulant tubes
(26.358, Sarstedt) and stored at −20◦C until further use. One
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hundred and forty-six microliters of blood were mixed with
12.5 µL antibiotic dilution in 0.9% NaCl to give concentrations
approximately corresponding to the acute toxicity experiments
(given that a standard mouse weighs 20 g and has an average
blood volume of 1.46ml), namely 250µg/mLMP196. In addition
500 µg/mL MP196 were tested. 0.9% NaCl and 5% DMSO
were used as negative controls. Samples were microscopically
examined after 30 min incubation at room temperature using
a Nikon Eclipse Ti equipped with a CFI Plan Apochromat DM
100x phase contrast oil objective, an Intensilight HG 130W lamp,
a C11440-22CU Hamamatsu ORCA camera, and NIS elements
software, version 4.20.01.
Hemolysis of Murine Red Blood Cells
Mouse blood was obtained as described above for the phase
contrast microscopy. The red blood cells were prepared from
these murine samples as described in Albada et al. for human
erythrocytes. The hemolytic activity of MP196 was determined
as described in the same reference (Albada et al., 2012a).
MP196 was tested at 250 and 500 µg/ml, and 5% DMSO
and 1% triton X-100 served as negative and positive controls,
respectively.
RESULTS AND DISCUSSION
We determined the minimal inhibitory concentrations (MICs)
against our model organism B. subtilis and several Gram-
positive and Gram-negative bacterial strains of clinical relevance
(Table 1). MP196 displayed decent activity against B. subtilis,
the S. aureus type strain DSM 20231, the MRSA type strain
ATCC43300, as well as the vancomycin-intermediate (VISA)
strain SG511, which carries a graS mutation that renders this
strain sensitive to antimicrobial peptides (Sass and Bierbaum,
2009). MIC values against the clinical S. aureus isolates COL
(MRSA) and Mu50 (VISA strain) were four to eight-fold higher
compared to the S. aureus type strain (DSM 20231), suggesting
that MP196 is not effective against all MRSA. Activity against
Gram-negative E. coli and A. baumannii was comparatively weak
and MP196 was not active against P. aeruginosa PA01, which
displays an intrinsically high antibiotic resistance.
Despite good in vitro activity, the in vivo activity of antibiotics
in general but antimicrobial peptides in particular might be
compromised by high affinity to blood serum proteins (Rolinson
and Sutherland, 1965). Antimicrobial activity of MP196 in the
presence of bovine serum was 50%, thus ∼50% of MP196 is
bound to serum proteins. Therefore, we would not predict serum
binding to be a limiting factor.
An important property of successful antibiotics is how fast
they are able to kill bacteria. The more rapidly an antibiotic
acts, the more restricted are the possibilities for bacteria to
adapt to and survive antibiotic stress. Therefore, we determined
short-time survival rates 10 min after antibiotic treatment.
At two-fold MIC MP196 was rapidly bactericidal against B.
subtilis killing 97% of an inoculum of 5 × 105 CFU/mL. This
3% percent survival is comparable with that after exposure to
two-fold MIC of the pore-forming antimicrobial peptide aurein
2.2 (0% survival) and the membrane-targeting peptide mimic
FcPNA (5% survival). The bacteriostatic folate biosynthesis
inhibitor trimethoprim was included as control (95%
survival).
Since MP196 targets bacterial membrane lipids (Wenzel
et al., 2014) and displays fast killing kinetics, it appears
likely that bacteria cannot easily develop resistance against this
peptide antibiotic. We determined the resistance frequency of
B. subtilis exposed to four-fold MIC for 24 and 48 h. In fact, no
resistant colonies could be found. Rifampicin and erythromycin,
antibiotics with single protein targets, served as controls
displaying resistance frequencies of 1.35 × 10−7 and 2.5 ×
10−8, respectively. These data show that resistance development
is unlikely to be a major roadblock for further development
of MP196-based antibacterial peptides. Past experience has
taught us that with antibiotic use eventually comes antibiotic
resistance, even for antibiotics targeting the membrane and other
complex targets such as polymyxins, daptomycin, or vancomycin
(Tenover, 2006; Falagas et al., 2010; Vilhena and Bettencourt,
2012) and we have no indication that MP196-based peptides will
be an exception.
MP196 was only slightly hemolytic even at very high peptide
concentrations and not significantly cytotoxic against human
liver carcinoma, colon adenocarcinoma, and breast cancer cell
lines (Albada et al., 2012a). In preparation of a mouse model
for acute toxicity, we additionally determined cytotoxicity for
human T-cell lymphoblasts and rat kidney epithelial cells. Using
an Alamar Blue assay, no cytotoxic effects were observed up to
200 µM (192 µg/mL). All these findings are well in line with
the high specificity of MP196 for bacterial over mammalian
membrane mimics (Wenzel et al., 2014). Encouraged by this,
we tested initial acute toxicity in mice. To this end, MP196
was directly injected into the tail vein. At low concentrations
(5 and 10 mg/kg body weight) the mouse showed signs of
excitement and indisposition with recovery within 25 min after
injection. At 25 mg/kg body weight paralysis of the hind legs
occurred and the mouse died within few minutes. This quick
reaction points to an acute toxicity effect rather than direct
cytotoxicity.
TABLE 1 | Minimal inhibitory concentrations of MP196 against different bacterial strains determined according to CLSI guidelines (µg/mL).
B. subtilis S. aureus E. coli A. baumannii P. aeruginosa
168 DSM20231
(type strain)
SG511 (VISA) ATCC43300
(MRSA)
COL (MRSA) Mu50
(VISA)
DSM30083
(type strain)
W3110 DSM30007
(type strain)
PA01
2 16 16 8 96 64 32 >64 32 >64
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FIGURE 1 | Activation of Nf-κB in RT4 bladder cells at concentrations
up to 25 µg/mL (A) and at 250 and 500 µg/mL (B).
FIGURE 2 | IL8 levels in RT4 bladder cells challenged with MP196 and
in DMSO and flagellin-treated controls.
A potentially fatal immune reaction is the cytokine storm.
Upon infection, cytokines are released by several immune cells
to attract and activate further useful immune cells, such as
T-cells or macrophages, which also secrete cytokines themselves
(Janeway et al., 2001). While this feedback loop is normally
carefully regulated, it can get out of control, especially when
the body is facing a previously unknown immunogen, in the
worst case leading to fatalities (Huang et al., 2005; Osterholm,
2005). Activation of NF-κB is a marker of cytokine release
(Gilmore, 2006), but using RT4 reporter bladder cells, no NF-
κB activation was observed at up to 25 µg/mL MP196 (12.5-fold
MIC against B. subtilis; Figure 1A) and even at concentrations of
250 and 500µg/mL no significant NF-κB activation was observed
(Figure 1B). RT4 bladder cells further showed no elevated IL8
levels after challenge with 250 µg/mL MP196 (Figure 2). These
data suggest that MP196 has no inflammatory activity when
applied to epithelial cells.
Since the presence of external peptidesmight stimulate allergic
reactions, we hypothesized that MP196-induced mortality might
be caused by anaphylactic shock. Therefore, we tested the
potential of MP196 to activate the release of histamine from
immune cells. Histamine is stored in mast cells and basophil
granulocytes and released upon cell activation by IgE (Janeway
et al., 2001). IgE-dependent basophil activation was tested by
flow cytometry using a two-color antibody reagent consisting
of anti-IgE-PE and anti-gp53-FITC (CD63). This assay allows
diagnosis of immediate-type hypersensitivity (type I reactions)
and indicates histamine release. We performed this assay with
blood from one donor and observed no IgE-dependent activation
after addition of up to 500 µg/mL MP196 (Figure 3). While
the preliminary tests are negative, it is important to note, that
more extensive analyses would be needed to fully rule out allergic
reactions.
Since we had no evidence of MP196 triggering immune
reactions, we attempted to determine solubility of MP196
in blood. Precipitated peptide could possibly clog blood
vessels or promote agglutination of blood cells. While we
could neither observe compound precipitation nor enhanced
agglutination, we observed significant damage of blood
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FIGURE 3 | IgE-dependent basophil activation measured by FACS. Anti-IgE (PE) reacts with human IgE and is used for the characterization of basophilic
granulocytes. Anti-gp53 (FITC) recognizes a glycoprotein expressed on activated basophils. The chemotactic peptide N-formyl-Met-Leu-Phe served as positive,
DMSO as negative control.
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FIGURE 4 | Phase contrast images of whole mouse blood mixed with MP196. Five percent DMSO is the maximum DMSO concentration reached by diluting
MP196 from the stock solution. Scale bar represents 20 µm.
cells (Figure 4). At 250 µg/mL, MP196 caused shrinking of
erythrocytes. Further increasing the concentration to 500 µg/mL
MP196 led to drastic morphological changes culminating in
erythrocyte lysis. In a previous study, similar concentrations
of peptide caused hemolysis of human erythrocytes of up
to 17% at 500 µg/mL (Albada et al., 2012a). Using the
same protocol described by Albada et al. we determined
14 and 23% lysis of murine erythrocytes at 250 and 500
µg/mL, respectively. Apparently, MP196 causes severe
erythrocyte damage the severity of which was misjudged as
“slight hemolysis” by a standard absorption-based hemolysis
assay, suggesting that blood cells should also be monitored
microscopically.
Taken together, two challenges for development of MP196
derivatives were identified in this study, one being the spectrum
of activity and the second being toxicity toward blood cells.
We believe that both challenges can be addressed by compound
derivatization. First steps in this direction have been taken.
The spectrum of activity has successfully been tackled by
structural optimization programs. Adding a lipidated lysine side
chain resulted in peptides with broad-spectrum and/or excellent
anti-MRSA activity (Albada et al., 2012b). Lipidation also
increased hemolysis, which has been addressed by systematically
exchanging L- with D-amino acids resulting in non-hemolytic
peptides with excellent activities against multi-resistant bacteria
(Albada et al., 2013). The next step will be to investigate
some of these advanced derivatives with regard to their
toxicity.
CONCLUSIONS
MP196 is a promising antibiotic lead structure for it kills
bacteria rapidly, and, due to its multiple mechanisms, is not
prone to be compromised by resistance development due to
point mutations. All MP196 derivatives tested so far displayed
the same mechanism of action as the parent compound
(Wenzel et al., 2014, 2016), giving reason to believe that the
concomitant advantages will bemaintained in further derivatives.
Serum binding is moderate and not perceived to become
a limiting factor. MP196 is not equally effective against all
MRSA or VISA strains and only weakly active against Gram-
negative bacteria. Most importantly, acute toxicity was observed
in mice dosed intravenously, likely as a result of toxicity
toward erythrocytes. Structural optimization programs exploring
peptide lipidation and L- to D-exchange show that peptides with
broad-spectrum and/or excellent anti-MRSA activity (Albada
et al., 2012b) and very low hemolytic activity (Albada et al.,
2013) can be obtained. As the next step toward in vivo
efficacy studies, these derivatives should be investigated for their
effects on erythrocytes and, where appropriate, tested for acute
toxicity.
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